MIME-Version: 1.0 Content-Type: multipart/related; boundary="----=_NextPart_01CAE7DE.8C09D110" This document is a Single File Web Page, also known as a Web Archive file. If you are seeing this message, your browser or editor doesn't support Web Archive files. Please download a browser that supports Web Archive, such as Windows® Internet Explorer®. ------=_NextPart_01CAE7DE.8C09D110 Content-Location: file:///C:/2818C811/1_2_JTEP_Vol_1_No_1.htm Content-Transfer-Encoding: quoted-printable Content-Type: text/html; charset="us-ascii"
IS=
SN
1916-6958
20=
10;
Volume 1 (Number 1): Pages 1-2
EDITORIAL
Good news: the Journal =
of
Theoretical and Experimental Pharmacology was born
Alejandro A.
NAVA-OCAMPOa,b
aDepartment of
Pharmacology & Toxicology, Faculty of Medicine,
bPharmaReasons, =
Correspondence=
span>:
editor.jtep@premiumreasons.com
The story on how this journal was planned is full =
of
anecdotes, friendship, and passion for work. However, I am sure that none of
members of the small group of colleagues who conceived the original idea of=
the
journal realized all the difficulties that would need to be sorted out to s=
ee
the first issue of the journal published.
The Journal of Theoretical and Experimental
Pharmacology welcomes any pharmacological research performed in silico, in
vitro, and in experimental animal models including computer simulations
with potential pharmacological interest; SAR and QSAR analyses; dose-respon=
se
evaluations; drug-drug interactions; drug effects at cellular and sub-cellu=
lar
levels; in vitro and in vivo metabolic studies; and
pharmacokinetic, pharmacodynamic, and teratogenic studies. The journal=
is
also accepting for consideration for publication studies in the field of
pharmacogenetics, pharmacogenomics, and preclinical toxicology.
Studies evaluating the effects of vitamins, hormon=
es,
immunological mediators, or chemicals are also welcomed if any of the topics
mentioned above are the focus of the study. At this time, only invited revi=
ew
articles are being accepted. However, systematic reviews and meta-analysis =
of
preclinical pharmacological studies are also welcomed through the stan=
dard
submission process.
The journal will also consider for publication
manuscripts devoted to the analysis of philosophical and ethical aspects of
biomedical sciences. These latter topics are intended to enrich the content=
of
the journal and to make it an open space where ethical and philosophical
dilemmas can be analyzed and debated.
I am excited by the response of colleagues from ar=
ound
the world to my invitation to join us in this adventure. Currently, 24 scie=
ntists
from 13 different countries around the world are members of the Editorial
Board. In this very first issue the journal publishes two review papers and=
two
original studies. All of them are of such a high quality that I should thank
the authors, including my Mexican colleagues, for considering this journal =
as
their option for publishing these papers instead of preferring well-establi=
shed
journals.
SERAFIM et al. [1] reviewed the
potential role of several phenolic acids and derivatives as anti-cancer age=
nts,
highlighting the role of mitochondria as a primary subcellular target for t=
his
class of compounds. Plant-derived phenolic compounds are widely consumed in=
a
normal diet, especially in fruits and vegetables. Interestingly, phenolic a=
cids
have been reported to display antiproliferative activity by promoting selec=
tive
induction of tumor cell apoptosis and by triggering the mitochondrial pathw=
ay
for apoptosis. CANAPARO & SERPE [2] reviewed sing=
le
nucleotide polymorphisms as a source of human genetic and phenotypic variat=
ion
and their contribution to the variability of drug action. However, as the
authors duly noted, any time genetics plays a role modifying drug effects,
there likely is a complex interplay of several genes rather than the action=
of
a single one.
GONZÁLEZ-LOZANO et al.
The journal is published electronically in the Eng=
lish
language only. However, the abstracts are available in three different
languages. Translation of the abstracts to French and Spanish was made poss=
ible
by colleagues who volunteered for this task.
This issue was supported by submission fees for
original papers as well as by generous support from PharmaReasons, Toronto,=
Canada.
However, the final acceptance of the manuscripts was independent of the
journal’s supporter. All the manuscripts can be downloaded at no cost=
.
As Editor, I express gratitude to my friends and
colleagues who have worked alongside me since the beginning of this project.
The authors and the readers of this journal deserve a special note of grati=
tude
for trusting us.
[1]
[3]
© PremiumReasons
N=
AVA-OCAMPO &=
nbsp; &nbs=
p; &=
nbsp; &nbs=
p; &=
nbsp; &nbs=
p; &=
nbsp; &nbs=
p; &=
nbsp; &nbs=
p; &=
nbsp; 2
&= nbsp; &nbs= p; &= nbsp; &nbs= p; &= nbsp; &nbs= p; &= nbsp; &nbs= p;